
Topic
Oncology
HER2-targeted therapy, tumor-type access, buy-and-bill reimbursement, oncology biosimilars, and cancer drug coverage.

Pipeline· August 11, 2026 · 14 min read
By Ran Chen#FDA Approval#Oncology#Bispecific Antibody

Approvals· August 10, 2026 · 14 min read
177Lu-Edotreotide (ITM-11) for GEP-NET: COMPETE Phase 3 Data and Lutathera Access
By Ran Chen#Radiolabeled Therapy#Oncology#FDA Approval

Policy· August 8, 2026 · 14 min read
EU Joint Clinical Assessments under the HTA Regulation: 2026 market access guide

Deals· August 8, 2026 · 15 min read
Servier's $2.5B Day One deal: tovorafenib (Ojemda) & first EU JCA completion
By Ran Chen#Servier#Day One#Tovorafenib

Approvals· August 7, 2026 · 14 min read
Iberdomide FDA PDUFA review: first-in-class CELMoD for multiple myeloma
By Ran Chen#FDA Approval#Multiple Myeloma#Oncology

Manufacturing· August 5, 2026 · 21 min read
2026 oncology injectable shortage: ifosfamide, carboplatin & buy-and-bill
By Ran Chen#Supply Chain#Oncology#Manufacturing

Pipeline· August 2, 2026 · 26 min read
In Vivo CAR-T by the Numbers 2026: $17.9B in Deals vs 23 Phase 1 Trials
By Ran Chen#CAR-T#Clinical Trials#Oncology

Pipeline· July 30, 2026 · 19 min read
Companion Diagnostics (2026): FDA PMA Supplement Expansion & Device Landscape
By Ran Chen#Companion Diagnostic#FDA Approval#Oncology

Pipeline· July 23, 2026 · 21 min read
Bispecific Antibody & T-Cell Engager Clinical Trials by the Numbers (2026)

Deals· July 23, 2026 · 17 min read